Oct 15, 2008 - Inspire Pharmaceuticals, Inc. announced today that the U.S. Patent and Trademark Office has issued a method of treatment patent related to Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis. This patent, U.S. Patent No. 7,429,602, entitled "Treating Conjunctivitis by Administering an Epinastine Solution to the Conjunctiva," was issued to Boehringer Ingelheim International GmbH, the developer of the invention, and expires on November 29, 2020.
The details can be read here.
No comments:
Post a Comment